Involved-Field Irradiation in Combination with Total-Body Irradiation (TBI) Does Not Increase Short-Term Toxicity Compared to TBI Alone in Patients with Advanced-Stage Low-Grade Non-Hodgkin Lymphoma

Ott, Marcel; Schmidberger, Heinz; Wörmann, Bernhard; Albrecht, Clemens; Pradier, Olivier; Hess, Clemens F.

doi:10.1007/s00066-002-0932-9

Cited by 5 publications

(2 citation statements)

References 40 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on the simulation films, verification films and radiation treatment protocols of the patients in the HD10 and HD11 [22] as defined in the study protocol followed by faults in the RT technique ( Figure 5). A common failure was, e.g., the usage of > 10-MeV photons.…”

Section: Retrospective Analysis Of the Adequacy Of The Performed Invomentioning

confidence: 99%

The Development of Quality Assurance Programs for Radiotherapy within the German Hodgkin Study Group (GHSG)

Müller

Eich

2005

Strahlenther Onkol

View full text Add to dashboard Cite

Today, radiation oncologists in the GHSG perform a continuous and efficient QAP to improve treatment quality of study patients. For early favorable and unfavorable HL a central prospective review of all diagnostic imaging is performed by expert radiation oncologists to control the disease extension and to define the IF treatment volume. Retrospective analysis of RT portals by an expert panel detects faults in the applied irradiation. Participants are trained on the definition of IF-RT by workshops on the occasion of annual GHSG meetings and on the annual meetings of the German Society of Therapeutic Radiation Oncology (DEGRO). For the advanced stages a multidisciplinary panel evaluates the treatment response to chemotherapy. Patients with a poor response receive additional RT due to the panel's recommendation. The introduction of teleradiotherapy into the GHSG trials improves the dialogue between the central RT reference center and study participants and thus contributes to high RT quality for study patients.

show abstract

Section: Retrospective Analysis Of the Adequacy Of The Performed Invomentioning

confidence: 99%

The Development of Quality Assurance Programs for Radiotherapy within the German Hodgkin Study Group (GHSG)

Müller

Eich

2005

Strahlenther Onkol

View full text Add to dashboard Cite

show abstract

“…However, it remains unclear whether it is justified to reserve WBRT for patients with overt recurrence after complete response to initial chemotherapy. As, especially in younger patients, toxicity of radiotherapy is mild, moderate doses of radiotherapy might optimize the therapeutic benefit in PCNSL patients with complete response to chemotherapy, as it has been recently demonstrated in extracerebral lymphomas [17,21,33,39]. Up to now, intrathecal chemotherapy has not found a defined role in the primary treatment of PCNSL [16].…”

Section: Discussionmentioning

confidence: 99%

Long-Term Survival Following Radiotherapy and Cytarabine Chemotherapy for Sporadic Primary Central Nervous System Lymphoma

et al. 2003

View full text Add to dashboard Cite

show abstract

Extranodales Marginalzonen-B-Zell-Lymphom (MALT-Lymphom) der Konjunktiven und des Larynx

et al. 2003

View full text Add to dashboard Cite

Extranodal, primary low grade B-cell MALT-type lymphoma are rare. In the literature only few cases of each larynx- and conjunctival eyelid involvement described. The radiotherapy has been reported to achieve a long time of relapse-free interval. The present case demonstrates, that even the recurrence of an extranodal, primary low-grade B-cell MALT-type lymphoma responds well to local radiotherapy and can also have a long period of no evidence of disease.

show abstract

Involved-Field Irradiation in Combination with Total-Body Irradiation (TBI) Does Not Increase Short-Term Toxicity Compared to TBI Alone in Patients with Advanced-Stage Low-Grade Non-Hodgkin Lymphoma

Abstract: HDT including TBI and prior IF-RT is feasible without excess morbidity. Careful follow-up is required to detect myelodysplastic syndrome or endocrine changes of ovarian or testicular function.

Cited by 5 publications

References 40 publications

The Development of Quality Assurance Programs for Radiotherapy within the German Hodgkin Study Group (GHSG)

The Development of Quality Assurance Programs for Radiotherapy within the German Hodgkin Study Group (GHSG)

Long-Term Survival Following Radiotherapy and Cytarabine Chemotherapy for Sporadic Primary Central Nervous System Lymphoma

Extranodales Marginalzonen-B-Zell-Lymphom (MALT-Lymphom) der Konjunktiven und des Larynx

Contact Info

Product

Resources

About